These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 8844341

  • 1. Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II study.
    Lissoni P, Vigorè L, Rescaldani R, Rovelli F, Brivio F, Giani L, Barni S, Tancini G, Ardizzoia A, Viganò MG.
    J Biol Regul Homeost Agents; 1995; 9(4):155-8. PubMed ID: 8844341
    [Abstract] [Full Text] [Related]

  • 2. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
    Lissoni P, Bolis S, Brivio F, Fumagalli L.
    Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
    [Abstract] [Full Text] [Related]

  • 3. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
    Lissoni P, Brivio F, Brivio O, Fumagalli L, Gramazio F, Rossi M, Emanuelli G, Alderi G, Lavorato F.
    J Biol Regul Homeost Agents; 1995; 9(1):31-3. PubMed ID: 8553906
    [Abstract] [Full Text] [Related]

  • 4. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
    Lissoni P, Malugani F, Malysheva O, Kozlov V, Laudon M, Conti A, Maestroni G.
    Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.
    Lissoni P, Barni S, Ardizzoia A, Brivio F, Tancini G, Conti A, Maestroni GJ.
    J Biol Regul Homeost Agents; 1992 Aug; 6(4):132-6. PubMed ID: 1296454
    [Abstract] [Full Text] [Related]

  • 7. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P, Vaghi M, Ardizzoia A, Malugani F, Fumagalli E, Bordin V, Fumagalli L, Bordoni A, Mengo S, Gardani GS, Tancini G.
    In Vivo; 2002 Aug; 16(2):93-6. PubMed ID: 12073777
    [Abstract] [Full Text] [Related]

  • 8. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
    Lissoni P, Brivio F, Fumagalli L, Messina G, Vigoré L, Parolini D, Colciago M, Rovelli F.
    Anticancer Res; 2008 Aug; 28(2B):1377-81. PubMed ID: 18505083
    [Abstract] [Full Text] [Related]

  • 9. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients.
    Romano F, Piacentini MG, Franciosi C, Caprotti R, De Fina S, Cesana G, Uggeri F, Conti M, Uggeri F.
    Hepatogastroenterology; 2004 Aug; 51(60):1872-6. PubMed ID: 15532847
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study.
    Lissoni P, Barni S, Brivio F, Rossini F, Fumagalli L, Tancini G.
    J Biol Regul Homeost Agents; 1995 Aug; 9(2):52-4. PubMed ID: 9127633
    [Abstract] [Full Text] [Related]

  • 12. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
    Lissoni P, Brivio F, Barni S, Tancini G, Cattaneo G, Archili C, Conti A, Maestroni GJ.
    Anticancer Res; 1990 Aug; 10(6):1759-61. PubMed ID: 2285255
    [Abstract] [Full Text] [Related]

  • 13. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
    Lissoni P, Barni S, Ardizzoia A, Olivini G, Brivio F, Tisi E, Tancini G, Characiejus D, Kothari L.
    J Biol Regul Homeost Agents; 1993 Aug; 7(4):121-5. PubMed ID: 8023699
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.
    Tambussi G, Ghezzi S, Nozza S, Vallanti G, Magenta L, Guffanti M, Brambilla A, Vicenzi E, Carrera P, Racca S, Soldini L, Gianotti N, Murone M, Veglia F, Poli G, Lazzarin A.
    J Infect Dis; 2001 May 15; 183(10):1476-84. PubMed ID: 11319683
    [Abstract] [Full Text] [Related]

  • 16. Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment.
    David D, Naït-Ighil L, Dupont B, Maral J, Gachot B, Thèze J.
    J Infect Dis; 2001 Mar 01; 183(5):730-5. PubMed ID: 11181149
    [Abstract] [Full Text] [Related]

  • 17. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection.
    Davey RT, Chaitt DG, Albert JM, Piscitelli SC, Kovacs JA, Walker RE, Falloon J, Polis MA, Metcalf JA, Masur H, Dewar R, Baseler M, Fyfe G, Giedlin MA, Lane HC.
    J Infect Dis; 1999 Apr 01; 179(4):849-58. PubMed ID: 10068580
    [Abstract] [Full Text] [Related]

  • 18. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
    Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, Erice A, Bucy RP, Kilby JM, Lederman MM, Hamilton CD, Lertora J, White BL, Tebas P, Duliege AM, Pollard RB, AIDS Clinical Trials Group 328 Study Team.
    Arch Intern Med; 2007 Mar 26; 167(6):597-605. PubMed ID: 17389292
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.